Bibliographic record
Abstract
The Formulary Management Expert Committee (FMEC) recommends that nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N + AVD) be reimbursed for the first-line treatment of stage III and stage IV classic Hodgkin lymphoma in patients 12 years of age and older, provided certain conditions are met. N + AVD should only be reimbursed for the first-line treatment of stage III and stage IV classic Hodgkin lymphoma in patients 12 years of age and older who do not have significant active autoimmune disease. When comparing N + AVD to brentuximab vedotin (BV) in combination with doxorubicin (Adriamycin), vinblastine, and dacarbazine (AVD), no price reduction is required to achieve cost-effectiveness, given that N + AVD has a lower drug cost and better clinical outcomes. Based on the Canada’s Drug Agency assessment of the clinical evidence, it was determined that there is not enough evidence to justify a greater cost for N + AVD compared with BV in combination with doxorubicin (Adriamycin), vincristine, etoposide, prednisone, and cyclophosphamide (BV + AVEPC).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.031 | 0.017 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".